Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Effect of montelukast on platelet activating factor- and tachykinin induced mucus secretion in the rat | Journal of Occupational Medicine and Toxicology BioMed Central Research Open Access Effect of montelukast on platelet activating factor- and tachykinin induced mucus secretion in the rat Rene Schmidt1 Petra Staats2 David A Groneberg3 and Ulrich Wagner 4 Address Department of Anesthesiology University Medical Center Hugstetter Strasse 55 D-79106 Freiburg Germany 2Department of Medicine Division of Pneumology University Medical Center Baldingerstrasse D-35043 Marburg Germany institute of Occupational Medicine Charité - Universitaetsmedizin Free University and Humboldt University Augustenburger Platz 1 D-13353 Berlin Germany and 4Department of Internal Medicine Division of Pneumology Klinik Loewenstein Geifihoelzle 62 D-74245 Loewenstein Germany Email Rene Schmidt - rene.schmidt@uniklinik-freiburg.de Petra Staats - staats@med.uni-marburg.de David A Groneberg - david.groneberg@charite.de Ulrich Wagner - ulrich.wagner@klinik-loewenstein.de Corresponding author Published 20 February 2008 Received 7 January 2008 . J -r .r . n r Accepted 20 February 2008 Journal of Occupational Medicine and Toxicology 2008 3 5 doi 10.ll 86 1745-6673-3-5 This article is available from http www.occup-med.cOm content 3 1 5 2008 Schmidt et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Platelet activating factor and tachykinins substance P neurokinin A neurokinin B are important mediators contributing to increased airway secretion in the context of different types of respiratory diseases including acute and chronic asthma. Leukotriene receptor antagonists are recommended as add-on therapy for this disease. The cys-leukotriene-1 receptor antagonist montelukast has been used in clinical asthma therapy during the last years. .
